Adeona Pharmaceuticals, Inc. (AMEX:AEN)

zzlangerhans (99.27) Submitted: 12/31/2011 2:19:11 AM : Start Price: $1.26 AEN Score: -107.80

I figured we'd have to wait until the Trimesta phase II trial drew close to completion before seeing Adeona rise from the Zinthionein ashes, but the company surprised me by pulling out yet another moonshot drug candidate. As if first-in-class drugs for Alzheimer's disease, multiple sclerosis, and fibromyalgia weren't enough, the company has now announced a farfetched partnership with Intrexon to develop gene therapy for pulmonary artery hypertension. Not bad for a company with a 15M market cap at the time of the announcement and 7M in the bank.

Needless to say, Adeona doesn't have a chance in Hell of bringing this highly speculative partnership to fruition. But they have managed to pump enough air back into their stock to make the inevitable upcoming dilutive financing much more rewarding.

vpdjuric (21.87) Submitted: 1/21/2011 3:02:18 AM : Start Price: $1.45 AEN Score: +82.64

I have to respectfully disagree with zz below. Zinth is definitely not a cure for Alzheimer's, and it is not advertised as such. It is a prescription medical food meant to slow cognitive degradation seen in Alzheimer's and similar diseases. The hypothesis is that since there is a significant correlation between zinc deficiency and degradation of cognitive function, taking zinc supplements may slow cognitive deterioration. Zinth is comprised of zinc and cysteine, and both components are generally regarded as safe, which reduces the number of hurdles Adeona has to overcome to get it to market. Zinth's differentiation from standard zinc supplements is its ease of digestion, whereas common zinc supplements commonly have side effects of indigestion, nausea, and heartburn. Anecdotal results have been positive so far:

http://www.crainsdetroit.com/article/20110102/SUB01/301029993/alzheimers-trial-may-win-deal-for-adeona-supplement-interests-drug-firms#

Beyond Zinth, they are also in various stages of testing 4 other drugs for drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis, a couple of which have blockbuster potential. The management team, led by Dr. Kuo, is stellar, and insiders own 47% of the company. Recently, they added Dr. Anand Prasad to the team, a pioneer in zinc research.

Adeona has already received term sheets for Zinth from potential pharma partners, but nothing has been announced yet. The final data from the Zinc trials will be announced in March, although a partnership may come before then. Kuo has announced that Adeona will hold an investor day on February 8th, during which he will discuss plans for Zinth. If a partnership deal has been signed, that would probably be the day he announced it...

staraman (< 20) Submitted: 9/25/2010 11:36:28 AM : Start Price: $0.81 AEN Score: +217.59

AEN has formed strong support at around 80 cents. The chart looks good from here and there some catalysts coming in 2011

schrld (< 20) Submitted: 10/30/2007 7:18:45 PM : Start Price: $6.12 AEN Score: -47.14

this co is incredibly overlooked. It is less than 6 months from having a drg on the market and has a full pipeline. At a cap of only 100million and a float of only 5 million! this stock could have a powerful explosion as their story unfolds and th market becomes aware of them.

SPECTRE2147 (57.28) Submitted: 10/25/2007 10:17:16 AM : Start Price: $6.92 AEN Score: -53.45

GOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOD

samsung2008 (< 20) Submitted: 8/18/2007 12:03:34 AM : Start Price: $6.10 AEN Score: -53.00

This stock will explode up one day, maybe several days, maybe for months...when the right news hits. News not to far away.

This stock could hold up well in down turns and I expect if Gen. Market conditions improve to the upside, PP could do very very well.

Good products in clinical testing, but market not to far away.